SOUTH SAN FRANCISCO, Calif.,
March 8, 2022 /PRNewswire/ -- IDEAYA
Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, announced plans to issue a
pre-market press release and host an Investor Webcast on
Tuesday, March 15, 2022 to discuss
interim clinical data for IDE397, a potential best-in-class MAT2A
inhibitor being evaluated in a Phase 1 Clinical Trial (NCT
04794699) in patients having tumors with MTAP deletion.
IDEAYA will host a conference call and webcast at 8:30 a.m.
ET on Tuesday, March 15, 2022. The agenda topics will
include an update on interim clinical data from the ongoing IDE397
Phase 1 clinical trial dose escalation, including a summary of
adverse events and pharmacokinetic, plasma pharmacodynamic and
tumor pharmacodynamic data. The company will also report
fourth quarter and full year 2021 financial results and provide
other corporate updates.
The link to the webcast and dial-in instructions for the
conference call will be available through the Investor
Relations Events section of the Company's website at:
https://ir.ideayabio.com/events. An archived replay will be
accessible for 90 days following the event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates capabilities in
identifying and validating translational biomarkers with drug
discovery to select patient populations most likely to benefit from
its targeted therapies. IDEAYA is applying its early research and
drug discovery capabilities to synthetic lethality – which
represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's Annual
Report on Form 10-K filed on March 15,
2022 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-investor-webcast-to-report-interim-ide397-phase-1-clinical-data-and-corporate-update-301497409.html
SOURCE IDEAYA Biosciences, Inc.